Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of combining anlotinib hydrochloride capsules with penpulimab injection as an additional treatment after radical surgery or ablation for patients with hepatocellular carcinoma HCC who are at high risk of cancer returning. This Phase 3 randomized, double-blind, placebo-controlled study aims to compare this combination therapy to a placebo to assess recurrence-free survival RFS over a period of up to three years. Participants receive either the anlotinib capsules plus penpulimab injection or matching placebos in 21-day treatment cycles. The study groups include an experimental arm receiving both active drugs and a control arm receiving placebo capsules and injections. This approach helps researchers understand how well the combination works in preventing cancer recurrence after initial treatment. Throughout the study, participants will have their health monitored regularly, including assessments of recurrence-free survival, time to cancer recurrence, time to spread outside the liver or vascular invasion, overall survival, and response rate after any recurrence. These evaluations will occur from the start of the study and continue for up to three years to track long-term outcomes and safety.
Actively Recruiting
Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.
Actively Recruiting
Researchers are evaluating the safety of inhaled TQC3721 suspension, a Phosphodiesterase34 inhibitor, in patients with moderate to severe Chronic Obstructive Pulmonary Disease COPD. This phase 3 study aims to observe adverse effects and lung function changes, providing valuable information about the treatment in this patient group. Participants receive TQC3721 suspension via inhalation at a dose of 6mg2ml twice daily. Two groups are studied one group uses the suspension for 24 weeks, and the other for 12 weeks. The study includes an extended observation period for safety in the longer treatment group. During the trial, participants undergo lung function tests measuring the forced expiratory volume in 1 second FEV1, and lab tests to monitor for adverse events and abnormalities. The study tracks COPD exacerbations and other health changes for up to 48 weeks. Participants are monitored regularly to assess treatment safety and lung function over time.
Actively Recruiting
Researchers are evaluating and comparing the effects of total intravenous anesthesia using remimazolam versus propofol in patients at moderate to high risk undergoing major elective noncardiac surgery under general anesthesia. This randomized controlled trial aims to determine if remimazolam can increase the number of days patients are alive and out of the hospital within 30 days after surgery. The study is conducted by Nanfang Hospital, Southern Medical University and is classified as a phase 4 trial. Participants receive either remimazolam or propofol as anesthesia. Remimazolam is given intravenously at 6-12 mgkgh for induction and 1.0-2.0 mgkgh for maintenance, adjusted to keep the Bispectral Index between 40 and 60. Propofol is administered intravenously at 1.5-2.5 mgkg for induction and 4-12 mgkgh for maintenance, also titrated to maintain the same Bispectral Index range. These dosing strategies help monitor and control anesthesia depth during surgery. During the study, participants will be closely monitored for outcomes including days alive and out of hospital at 30 days after randomization, all-cause mortality within 30 days, length of hospital stay, unplanned re-hospitalizations, postoperative complications, and quality of recovery on the first day after surgery. The trial involves double-blind randomization and includes follow-up assessments at 30 days to gather comprehensive data on recovery and safety.
Actively Recruiting
Researchers are evaluating the effects of high caloric oral nutritional supplements on growth, development, and related health aspects in malnourished children aged 1 to 3 years. This study aims to assess body proportion, weight, linear growth, neuropsychological development, gut health, immune function, and quality of life, while also evaluating the safety of these supplements. The trial addresses a lack of multicenter clinical data on these supplements in malnourished Chinese children and seeks to provide evidence for clinical intervention strategies. Participants will be randomly assigned to one of two groups the experimental group receiving nutritional education plus daily high caloric oral nutritional supplements that provide 30% of energy needs, and the control group receiving nutritional education and dietary guidance only. The intervention lasts 12 months, with the supplement feeding reviewed at 6 months to decide on continuation. Nutritional education is delivered via WeChat or text messages, and dietary guidance is provided by pediatricians at regular follow-up visits. Throughout the study, participants will be followed at 0, 1, 2, 3, 6, and 12 months. Researchers will collect dietary diaries, physical measurements, developmental tests, quality of life questionnaires, gut health and infectious disease assessments, and laboratory tests including blood, urine, liver, and kidney function. The main outcome measured is the BMI for Age Z-score at 6 months. Safety and efficacy are monitored continuously to understand the impact of the supplement on growth and development in malnourished children.